Search
Levacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnThe production of levacetylmethadol in the US has ceased as well.[L44052,T862] … It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBuprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approvedCombination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist … The intention of substitution of illicit opioids with the long-acting opioids used in OAT is to prevent withdrawal symptomns for 24-36 hours following dosing to ultimately reduce cravings and drug-seeking
Mixtures: BUPRENORFINA E NALOXONE ETHYPHARM, BUPRENORFINA E NALOXONE ETHYPHARMCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCilazapril
go.drugbank.com/drugs/DB01340ApprovedInvestigationalCilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. … None of these varieties are available in the United States.
Categories: Agents Acting on the Renin-Angiotensin SystemSulfacetamide
go.drugbank.com/drugs/DB00634ApprovedAn anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.
Mixtures: Prascion TS, Sumaxin TSProducts: Re 10 WashBacillus calmette-guerin substrain connaught live antigen
go.drugbank.com/drugs/DB10804ApprovedInvestigationalWithdrawnor recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). … Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary
Olanzapine
go.drugbank.com/drugs/DB00334ApprovedInvestigational[A177011] Olanzapine was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.[T548] … The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeButorphanol
go.drugbank.com/drugs/DB00611ApprovedIllicitVet approvedIt is used in the management of severe pain.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOxolamine
go.drugbank.com/drugs/DB13216ApprovedOxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant [L5416]. It is listed as a prescription drug in New Zealand legislation [L5419]. … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422].
Mixtures: OLEDRO HOT D TEK DOZLUK EFERVESAN GRANÜL İÇEREN POŞET, 12 ADET, OLEDRO HOT D TEK DOZLUK EFERVESAN GRANÜL İÇEREN POŞET, 6 ADETBazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalIn 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as … the prevention of postmenopausal osteoporosis in women.
Categories: Sex Hormones and Modulators of the Genital SystemBenserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalA decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation … blood and to various extracerebral tissues.
Mixtures: MADOPAR 125 T, MADOPAR 125 T